×







We sell 100% Genuine & New Books only!

Pharmaceutical Economics and Policy Perspectives Promises and Problems 2018 Edition at Meripustak

Pharmaceutical Economics and Policy Perspectives Promises and Problems 2018 Edition by Stuart O. Schweitzer, Z. John Lu , Oxford

Books from same Author: Stuart O. Schweitzer, Z. John Lu

Books from same Publisher: Oxford

Related Category: Author List / Publisher List


  • Price: ₹ 6041.00/- [ 17.00% off ]

    Seller Price: ₹ 5014.00

Estimated Delivery Time : 4-5 Business Days

Sold By: Meripustak      Click for Bulk Order

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

We deliver across all postal codes in India

Orders Outside India


Add To Cart


Outside India Order Estimated Delivery Time
7-10 Business Days


  • We Deliver Across 100+ Countries

  • MeriPustak’s Books are 100% New & Original
  • General Information  
    Author(s)Stuart O. Schweitzer, Z. John Lu
    PublisherOxford
    ISBN9780190623784
    Pages432
    BindingHardback
    LanguageEnglish
    Publish YearJune 2018

    Description

    Oxford Pharmaceutical Economics and Policy Perspectives Promises and Problems 2018 Edition by Stuart O. Schweitzer, Z. John Lu

    Pharmaceuticals constitute a relatively small share of the total healthcare expenditure in most developed economies, and yet they play a critical role in the ongoing debate over how best to advance, improve, and afford healthcare. Despite this, and perhaps because of this, the industry has had, for many years, an outsized claim to fame and controversy, praise and criticisms, support and condemnation. Unfortunately, many participants in the debate do not fully
    understand the complexities of the industry and its role in the overall healthcare system.

    The analytical tools of economics provide a strong foundation for a better understanding of the dynamics of the pharmaceutical industry, its contribution to health and healthcare, its dual and often conflicting priorities of affordability and innovation, as well as the various private and public policy initiatives directed at the sector. This third edition of a uniquely comprehensive and balanced examination of the industry includes several new chapters on important topics such as the
    full-fledged generics sector, the arrival of biosimilars or generic biological drugs, the global consolidation of manufacturers, the evolving reimbursement landscape, and the emergence of the world's most populous nations, such as China, India, and Brazil, as both suppliers and consumers of pharmaceutical
    products. Other chapters have been fully rewritten or extensively updated, covering such important topics as the cost efficiency of research and development, pace of new innovations, economic evaluation and value-based pricing of drugs, and public and private interventions in the industry.

     

    Table of contents

    Introduction

    The Big Picture
    The Supply of Pharmaceuticals
    The Demand for Pharmaceuticals
    Pharmaceutical Prices
    International Price Comparisons
    Pharmaceutical Marketing
    Pharmaceutical Patents
    Regulatory Control of the Pharmaceutical Sector
    Timing of Pharmaceutical Approvals

    Part I. The Industry

    Chapter 1 The Pharmaceutical Industry

    The Competitive Structure of the Pharmaceutical Industry
    Pharmaceutical Research and Development
    Pharmaceutical R&D and Prices
    The Pharmaceutical Research and Approval Process
    Product Liability
    Increasing Private Sector Research Activity
    Drugs for Low-Income Countries
    The Role of Pharmaceutical Marketing in Prescribing Decisions
    Conclusions

    Chapter 2 The Biotechnology Industry

    Background
    What is Biotechnology?
    A Brief History of Modern Biotechnology Industry
    Factors Distinguishing the Biotechnology from the Pharmaceutical Industry
    Case Studies of Biotechnology Firm Growth and Failure
    Conclusion

    Chapter 3 Generics and Biosimilars

    Introduction
    A Brief History of Modern Generic Pharmaceutical Industry in the US
    The Structure of the Generic Pharmaceutical Industry
    Generic Entry and Price Competition in the Pharmaceutical Marketplace
    Generic Entry and Strategic Behavior
    Drug Shortage
    Economic Analysis of Drug Shortage
    The Emergence of Biosimilars
    Conclusion

    Chapter 4 The Global Pharmaceutical Industry

    Geographic Patterns of Pharmaceutical Production and Sales
    International Trade in Pharmaceutical Products
    Pharmaceutical Research and Development: An International View
    Does Government Drug Price Setting Influence R&D?
    Global Mergers and Acquisitions
    The Pharmaceutical Industry in Selected Countries and Regions
    The Chinese Pharmaceutical Industry
    Access to Appropriate Drugs in Developing Countries

    Part II. The Consumer

    Chapter 5 The Demand for Pharmaceuticals

    The Problem of Drug Expenditures
    How is Demand Determined?
    Pharmaceuticals and Other Health Services: Substitutes or Complements?
    The Changing Structure of the Pharmaceutical Market
    Conclusion

    Chapter 6 The Demand for Pharmaceuticals in Major International Markets

    Comparison of Pharmaceutical Spending across Global Markets
    Comparison of Pharmaceutical Consumption across Global Markets
    Demand for Pharmaceuticals in Japan
    Demand for Pharmaceuticals in China
    Demand for Pharmaceuticals in France and Germany
    Demand for Pharmaceuticals in the United Kingdom
    Demand for Pharmaceuticals in Canada
    Demand for Pharmaceuticals in Brazil
    Conclusion

    Part III. Pricing and Marketing of Pharmaceutical Products

    Chapter 7 Pharmaceutical Prices

    The Problem of Pharmaceutical Prices
    Pharmaceutical Prices Over Time
    Measuring Drug Prices: What Prices?
    Measuring Drug Prices: Rate of Change
    How Are Drug Prices Determined?
    Economic Models from Industrial Organization Literature
    Market Power, Generic Entry and Pricing

    Chapter 8 Economic Evaluation of New Drugs

    Optimizing Production of Health
    Cost-Benefit Analysis
    Cost-Effectiveness Analysis
    Cost-Utility Analysis
    Cost-Effectiveness League Table
    Policy Applications
    Conclusions

    Chapter 9 Pricing Pharmaceuticals in a World Environment

    Why Do Drug Prices Vary Across Country?
    Comprehensive Comparison of International Drug Prices
    Policy Implications
    Conclusion

    Chapter 10 Pharmaceutical Marketing

    Size of the Pharmaceutical Promotion Effort
    Pharmaceutical Promotion Directed at Healthcare Providers
    Pharmaceutical Promotion Aimed at Patients: Direct-to-Consumer Advertising (DTCA)
    Pharmaceutical Promotion to Third-Party Payers
    Regulation of Prescription Pharmaceutical Promotion
    False and Misleading Claims
    Off-Label Promotion
    Conclusion

    Part IV. Public Policies in the Pharmaceutical Market

    Chapter 11 Patent Protection

    Introduction
    Patent Law
    Patentability
    Patent Categories
    How Patents Are Obtained?
    What Protection Does a Patent Confer?
    Duration of Patent Protection
    Infringement of Patents
    Strategic Responses by Pharmaceutical Firms
    International Patent Treaties
    Patent Procedures under International Conventions
    Criticisms of the Patent System
    Patent and Societal Choice

    Chapter 12 Drug Approval Process in the United States

    The Drug Approval Process in the United States
    The Rising Cost of Pharmaceutical R&D
    Major Drug Legislations in the United States
    Annual NME Approvals by FDA since 2000
    Regulatory Approval of Generic Drugs in the US
    Regulatory Approval of Biosimilars in the US

    Chapter 13 Pharmaceutical Regulation in the European Union

    The European Union
    Move Toward a Single Market
    History of Drug Regulation in Europe
    Structure and Role of the European Medicines Agency
    Drug Review under the European Medicines Agency
    EU Rules on Labeling of Medicinal Products
    Regulations of Drug Advertising
    Pharmacovigilance
    Approval of Generic Drugs in the European Union
    Approval of Biosimilars in the European Union
    Comparison of International Drug Approval Lags

    Chapter 14 Pharmaceuticals and Public Policy: A Look Ahead

    Industry Structure
    The Nascent Biosimilar Sector
    Personalized Medicine and Digital Healthcare Information
    Artificial Intelligence and Medicine
    Outpatient Bundled Payment Program and Pharmaceuticals
    Pharmaceutical Prices
    The FDA
    Conclusion.



    Book Successfully Added To Your Cart